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Abstract Medulloblastoma, a small blue cell malignancy
of the cerebellum, is a major cause of morbidity and mor-
talityinpediatriconcology.Currentmechanismsforclinical
prognostication and stratiﬁcation include clinical factors
(age,presenceofmetastases,andextent ofresection)aswell
ashistologicalsubgrouping(classic,desmoplastic,andlarge
cell/anaplastic histology). Transcriptional proﬁling studies
of medulloblastoma cohorts from several research groups
around the globe have suggested the existence of multiple
distinct molecular subgroups that differ in their demo-
graphics, transcriptomes, somatic genetic events, and
clinical outcomes. Variations in the number, composition,
and nature of the subgroups betweenstudies brought about a
consensus conference in Boston in the fall of 2010. Dis-
cussants at the conference came to a consensus that the
evidence supported the existence of four main subgroups of
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DOI 10.1007/s00401-011-0922-zmedulloblastoma (Wnt, Shh, Group 3, and Group 4). Par-
ticipants outlined the demographic, transcriptional, genetic,
and clinical differences between the four subgroups. While
it is anticipated that the molecular classiﬁcation of medul-
loblastoma will continue to evolve and diversify in the
future as larger cohorts are studied at greater depth, herein
we outline the current consensus nomenclature, and the
differences between the medulloblastoma subgroups.
Keywords Medulloblastoma  Consensus  Subgroups 
SHH  WNT  Group 3  Group 4
Introduction
Current classiﬁcation schemes for medulloblastoma are
based primarily on morphology (histopathology), and
include variants such as desmoplastic/nodular, MBEN
(medulloblastoma with extensive nodularity), classic
medulloblastoma, large cell, and anaplastic medulloblas-
toma. With recent developments in the ability to monitor
transcription across the genome in the setting of a single
experiment, various groups have started to sub-classify
medulloblastoma on the basis of differences in the tran-
scriptome [36]. Several laboratories across the globe have
published on this topic in the recent past, with largely
convergent conclusions [2, 7, 14, 22, 28, 30, 48]. This
transcriptional approach to tumor sub-classiﬁcation has
also been applied to a number of different non-medullo-
blastoma histologies [4, 16, 18, 31, 35, 43], with the
underlying assumption that tumors with similar tran-
scriptomes will behave in a biologically similar manner,
allowing a transcriptionally driven classiﬁcation to serve as
a guide for successful anti-neoplastic therapy.
Thenumberof‘subgroups’ofmedulloblastomaidentiﬁed
among cohorts of medulloblastoma is largely dependant on
the number of individual tumors within a given cohort, with
larger cohorts identifying additional levels of hierarchical
complexity [7, 22, 28, 36]. On the basis of the published
literature, and some unpublished data presented at a recent
consensus conference in Boston, Massachusetts, members
frommanyofthelaboratoriespublishingonthistopicagreed
that there were four principal transcriptional subgroups of
medulloblastoma, with many of these subgroups showing a
subsequent level of hierarchical structure that will be des-
ignated the subtypes of the subgroups (Fig. 1). The true
number of subtypes for each of the subgroups is currently
unknown, but it is likely more than one subtype for each
subgroup. The four principal subgroups of medulloblastoma
were named as follows: Wnt, Shh, Group 3, and Group 4
(Fig. 2).TheWntandShh(SonicHedgehog)werenamedfor
thesignalingpathwaysthoughttoplayprominentrolesinthe
pathogenesis ofthat subgroup. Since less isknownabout the
biology of the remaining two subgroups, the consensus was
to retain generic names for the present until the underlying
biologydrivingthesesubgroupswasbetterdelineated.There
is evidence for the existence of subtypes within the sub-
groups, particularly for Group 3, which is also reﬂected by
thefactthatamongNon-WNT,Non-SHHtumors,theremay
be a small fraction of ‘‘intermediate’’ tumors that would be
assigned to Group 3 or Group 4 based on the clustering
algorithm applied [7]. While the subsets of the subgroups
seem readily apparent, they are notwell characterizedatthis
point and as such the consensus was to name them using
Greek letters (a, b, c, etc.) until additional characterization
was available from multiple centers, on much larger cohorts
(Fig. 1). Since the four groups as proposed are clearly dis-
tinct in terms of demographics, histology, DNA copy-
number aberrations, and clinical outcome as also nicely
summarizedinameta-analysispaperinthesameissueofthis
journal [21], the authors consider it highly useful to start
using these subgroups in the clinic. More speciﬁcally,
molecular subgrouping will not only contribute to identify
target cohorts for certain drugs (e.g., SHH inhibitors), but
also add signiﬁcantly to outcome prediction by the time of
diagnosis [21], much more than any of the established clin-
ical markers such as patient age, metastatic stage at
diagnosis, level of resection, and histological subtype
according to the WHO classiﬁcation [25]. To this end,
Table 1 summarizes markers that have been proposed to
perform subgrouping by immunostaining from various
groups. Although it is evident that few tumors will either be
positiveformorethanonemarkerornegativeforallmarkers
[28], it is encouraging that using two markers that are sup-
posedtoselectthesamesubgroup(suchasSFRP1andGAB1
for SHH tumors) resulted in a very high overlap in a study
published in the same issue of this journal [23]. In the fol-
lowing, the distinctive characteristics of these four core
subgroups are described in more detail.
Wnt subgroup
The best known of the medulloblastoma subgroups is the
Wnt subgroup due to its very good long-term prognosis in
comparison to other subgroups [8, 11, 13, 15, 22, 28, 39,
48]. Indeed, long-term survival rates for patients with Wnt
medulloblastoma likely exceed 90%, with those patients
who die succumbing more often to complications of ther-
apy or secondary neoplasms rather than to recurrent Wnt
medulloblastoma [12]. Germline mutations of the Wnt
pathway inhibitor APC predispose to Turcot syndrome,
which includes a proclivity to medulloblastoma, in addi-
tion, somatic mutations of CTNNB1 encoding b-catenin
have been found in sporadic medulloblastomas [19, 50].
These strong germline and somatic genetic data strongly
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123support an etiological role for canonical Wnt signaling in
the pathogenesis of this group of tumors, and lead to the
nomenclature of ‘Wnt subgroup medulloblastomas’.
Nearly all of the Wnt medulloblastomas studied to date
have classic histology. Wnt medulloblastomas are fre-
quently described as having CTNNB1 mutations, nuclear
Fig. 2 Comparison of the various subgroups of medulloblastoma including their afﬁliations with previously published papers on
medulloblastoma molecular subgrouping
Fig. 1 Dendrogram depicting the classiﬁcation of embryonal tumors
of the cerebellum. Medulloblastomas should be differentiated from
the less common ATRTs and ETANTRs of the cerebellum. Under the
current consensus classiﬁcation of medulloblastoma four principle
subgroups are identiﬁed: Wnt, Shh, Group 3, and Group 4. The
evidence suggests that each of the four principle subgroups will likely
have distinct ‘subsets’ that are biologically and clinically
homogeneous as compared to other subsets from within the same
subgroup. As the nature and number of subsets for each subgroup are
currently unknown, the consensus classiﬁcation suggests that each
subset be named using a Greek letter (a, b, c, etc.) until such time as
they are sufﬁciently characterized to be named based on their
molecular etiology
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123immunohistochemical staining for b-catenin, and mono-
somy six (deletion of one copy of chromosome 6 in the
tumor). Which, if any of these markers is a gold standard for
the diagnosis of Wnt medulloblastoma is unclear, as
medulloblastomaswithaclear Wnttranscriptional signature
thatdonothave monosomysixhave beenreported[28].The
recent report of a single medulloblastoma with mutations in
both CTNNB1 and PTCH also complicates the story [32].
Indeed,over-representationofgenesintheWntpathwayhas
also been reported in Shh and Group 3 medulloblastomas,
although this ﬁnding is of unknown signiﬁcance [28].
Medulloblastomas with large cell/anaplastic histology have
alsobeenreportedintheWntsubgroup,althoughtheyappear
to maintain the excellent prognosis associated with the Wnt
subgroup [12]. Which of monosomy 6, nuclear staining for
b-catenin, mutation of CTNNB1, immunohistochemical
stainingforDKK1[28,48],oratranscriptionalsignaturethat
clusters with other ‘Wnt’ tumors should be used as a gold
standard for the diagnosis of Wnt medulloblastoma awaits
further validation on larger cohorts of well-characterized
medulloblastomas.
Overall medulloblastoma is more common in males,
however,thegenderratioforWntmedulloblastomasisabout
1:1 male:female. Wnt medulloblastomas can occur at all
ages, but are uncommon in infants. Other than monosomy
six, there are few other regions of genetic ampliﬁcation or
deletion in the genome of Wnt medulloblastomas [28].
Recently a mouse model of Wnt medulloblastoma was
published, which suggested that Wnt medulloblastomas
arisefromthelowerrhombiclipofthecerebellum[17].This
mouse will undoubtedly serve as a valuable tool in the pre-
clinical assessment of novel therapeutics. As most patients
with Wnt medulloblastoma survive, it is possible that they
are being over treated with current therapies which are quite
morbid, and there is an active discussion of a clinical trial of
therapy de-escalation in this patient population.
Sonic hedgehog subgroup
The Shh group of medulloblastomas are named after the
Sonic Hedgehog signaling pathway, which is thought to
drive tumor initiation in many, if not all such cases. Indi-
viduals with germline mutations in the Shh receptor PTCH
have Gorlin syndrome, which includes a predisposition to
medulloblastoma [3, 47]. Similarly, individuals with germ-
line mutations of the Shh inhibitor SUFU are predisposed
to medulloblastoma, particularly infantile medulloblastoma
[5,33,42,46].Similarly,somaticmutationsofPTCH,SMO,
and SUFU, as well as ampliﬁcations of GLI1 and GLI2
have been found in sporadic medulloblastoma [27, 30, 46].
These genetic data implicating Shh signaling in the etiology
of this group of tumors has lead to the current proposal
to formally name them ‘Sonic Hedgehog’ subgroup
medulloblastomas.
Sonichedgehogsubgroupmedulloblastomashavelargely
beenidentiﬁedonthebasisoftranscriptionalproﬁling[7,22,
28, 29, 41, 48]. Others approaches to identify Shh medullo-
blastomas have included immunohistochemical staining for
SFRP1 [2, 28, 48], or GAB1 [11]. Deletion of chromosome
9q appears to be limited to Shh medulloblastomas, which is
appropriate as the PTCH gene is located at chromosome
9q22 [28]. The vast majority of published mouse models of
medulloblastomabelongtotheShhsubgroupoftumors[20].
The temporal incidence of human Shh medulloblastoma is
curiously dichotomous, in that it is very frequent in both
infants (0–3 years) and adults ([16 years), but much less
frequent in children (3–16 years). The extent to which adult
Table 1 Antibodies used for immunohistochemical assignment of medulloblastoma subgroup afﬁliation
Antigens Subgroup(s) Antibody sources Company (catalog#) Dilution(s) Reference(s)
CTNNB1 (nuclear) WNT Mouse monoclonal BD Transduction Laboratories (ab610154) 1:100
1:800
[8, 11–13, 28, 37]
Mouse monoclonal Ventana (760-4242) N/A [2, 14]
N/A Cell Signaling Technologies 1:500 [15, 39]
DKK1 WNT Mouse monoclonal Abnova (H00022943-M11) 1:100 [28, 37]
SFRP1 SHH Rabbit polyclonal Abcam (ab4193) 1:2,000 [28, 37, 38]
GLI1 SHH Rabbit polyclonal Millipore (ab3444) 1:5,000 [28]
Goat polyclonal Santa Cruz Biotechnology (sc-6152) N/A [2]
GAB1 SHH Rabbit polyclonal Abcam (ab27439) 1:50 [11]
FILA WNT/SHH Mouse monoclonal Fitzgerald (10R-F113A) 1:100 [11]
YAP1 WNT/SHH Mouse monoclonal Santa Cruz (sc-101199) 1:50 [11]
NPR3 Group C Rabbit polyclonal Abcam (ab37617) 1:200 [28, 37, 38]
Group C Rabbit polyclonal Sigma (HPA031065) 1:30 N/A
KCNA1 Group D Rabbit polyclonal Abcam (ab32433) 1:2,000 [28, 37, 38]
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123Shh medulloblastomas resemble infant Shh medulloblas-
toma remains to be determined by the analyses of larger
cohortsoftumors.Somerecent series[28],butnotothers [7]
have found a preponderance of females among Shh medul-
loblastoma. Taken into account all published studies, the
gender ratio is approximately 1:1. Most, if not all nodular/
desmoplasticmedulloblastomasbelongtotheShhsubgroup.
However, this is not an effective marker for the subgroup as
up to 50% of Shh subgroup medulloblastomas are not nod-
ular/desmoplastic. The prognosis of Shh medulloblastoma
appears to be similar to Group 4 medulloblastomas, and
intermediate between that Wnt medulloblastomas (good)
and Group 3 medulloblastomas (poor). The recent demon-
stration that small molecules targeting smoothened (SMO)
are highly effective, albeit temporarily, against Shh medul-
loblastoma underlines the urgent need to develop effective
and practical markers for Shh medulloblastoma [6, 40, 49].
Group 3
Group 3 tumors are mostly ‘classic’ medulloblastomas,
although they do encompass the majority of the LCA
tumors. The current gold standard for diagnosis of a Group
3 tumor is a transcriptional proﬁle that clusters with other
Group 3 tumors [7, 22, 28]. Immunohistochemical posi-
tivity for NPR3 has been suggested as a Group 3 marker
[28]. While Shh subgroup tumors have high levels of
expression of MYCN, and Wnt subgroup and Group 3
tumors have high levels of expression of MYC, whereas
Group 4 tumors have relatively low expression of both
MYC and MYCN, apart from the few cases that have MYCN
ampliﬁcation [20, 22, 28]. As such, it has been suggested
by one group that Group 3 tumors could be called the MYC
group [20]. Similarly, MYC ampliﬁcation (but not MYCN
ampliﬁcation) appears to be almost always limited to
Group 3 [7, 22, 28]. Ampliﬁcation and over-expression of
the medulloblastoma oncogene OTX2 appears to be
restricted to Group 3 and Group 4 tumors [1, 9, 10, 28].
Group 3 tumors over-express a number of genes that were
initially identiﬁed through their role in retinal develop-
ment, although the role of these genes in the pathogenesis
in Group 3 tumors is currently opaque [7, 22, 28]. Group 3
tumors are much more likely than Group 4 tumors to show
gain of chromosome 1q, and/or loss of chromosome 5q and
chromosome 10q.
Group 3 tumors occur more commonly in males than
females, and are found in infants and children, but are
almost neverobservedinadults. Group 3tumors have ahigh
incidence of LCA histology, and are very frequently met-
astatic [28]. Indeed, it has been suggested that prior
identiﬁcation of metastatic status as risk factor for poor
prognosis in medulloblastoma was in fact identifying a
group of patients enriched for Group 3 patients [28]. The
best evidence for a clear ‘subset of a subgroup’ in medul-
loblastoma to date is found in Group 3, in which one subset
(Group 3a) includes all of the patients with MYC ampliﬁ-
cations, and which assumes that most of the high risk of
recurrence and death associated with a Group 3 diagnosis.
Conversely, Group 3b patients were not found to harbor
MYC ampliﬁcations, and had a clinical outcome similar to
Group 4 patients [7]. This exciting ﬁnding awaits validation
in additional cohorts, and the development of clinically
expedient markers for the identiﬁcation of Group 3a and
Group 3b patients. Although Group 3 tumors are likely
more similar to Group 4 tumors than to Shh or Wnt tumors,
the demographic, clinical, transcriptional, and genetic dif-
ferences between the Group 3 and Group 4 suggest that they
are indeed distinct entities [22, 28]. Clearly, the terrible
prognosis of Group 3 patients indicates that the medullo-
blastoma communityneedstofocus furtheronthissubgroup
to develop practical biomarkers, understand its underlying
pathogenesis, and develop accurate mouse models.
Group 4
Group 4 medulloblastomas are the prototypical medullo-
blastoma: a 7-year-old boy with a classic histology
medulloblastoma that has an isochromosome 17q. As the
molecular pathogenesis of Group 4 tumors is not currently
clear, the generic name ‘Group 4’ has been chosen for the
current consensus nomenclature pending further insights.
Currently, Group 4 medulloblastomas are identiﬁed
through a transcriptional proﬁle that clusters with other
Group 4 medulloblastomas. KCNA1 has been suggested as
an immunohistochemical marker for Group 4 tumors but
requires validation in additional cohorts [7, 28]. Although
isochromosome 17q is also seen in Group 3 tumors (26%),
it is much more common in Group 4 tumors where it is the
most common cytogenetic change observed (66%) as also
seen in the meta-analysis paper by Kool et al. on all pub-
lished data sets in this issue of the journal [21, 28].
Similarly, isolated 17p deletion is seen in both Group 3 and
Group 4, but almost never in Wnt or Shh subgroup
medulloblastomas. The only other notable cytogenetic
change among Group 4 tumors is loss of the X chromo-
some, which is seen in 80% of females with Group 4
medulloblastoma. The high incidence of X chromosome
loss in females with Group 4 medulloblastomas is partic-
ularly poignant in light of the high male:female ratio in
Group 4 patients (2:1). Multiple publications have identi-
ﬁed over-representation of genes involved in neuronal
differentiation and neuronal development in Group 4
tumors, although neither the genetic basis, nor the clinical
relevance of this is yet apparent [7, 22, 28]. Group 4
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123patients have an intermediate prognosis, similar to indi-
viduals with Shh tumors. Although Group 4 tumors make
up[30% of all medulloblastomas, we probably understand
the least about the molecular pathogenesis of this subgroup,
and no mouse models of Group 4 have been reported.
Histology: special considerations
While most investigators in the ﬁeld feel strongly that
molecular markers will assume increasing importance in
the diagnosis and classiﬁcation of medulloblastoma in the
near future, still there will clearly be a role for histopa-
thology. True nodular/desmoplastic tumors, and likely all
of the MBENs belong to the Shh subgroup of tumors [11,
26]. Classic histology, however, is spread over all four of
the principal subgroups, and can even be difﬁcult to dis-
tinguish from atypical teratoid/rhaboid tumors on the basis
of morphology alone. Large cell/anaplastic tumors also
appear to be found in all four principal subgroups, although
the majority are Group 3. However, LCA histology main-
tains its prognostic signiﬁcance after accounting for
subgroup, and the diagnosis of LCA histology may there-
fore retain signiﬁcance in a ‘post-subgroup’ world [28]. We
would suggest, however, that the prognostic signiﬁcance of
LCA histology needs to be assessed separately in large
cohorts of each subgroup as the ﬁeld moves forward.
Adult medulloblastoma
The degree of molecular and clinical similarity between
adult and pediatric medulloblastoma is not entirely clear,
yet. Some authors have certainly reported distinct molec-
ular proﬁles [24] and clinical behavior [44, 45] when
comparing adults and children/infants. However, the dis-
tribution of cases across the subgroups is very different in
adults as compared to children [2, 28, 37, 38]. The most
comprehensive study on adult MB published to date sug-
gests that group 3 tumors are exceptionally rare in adults,
whereas SHH tumors comprise about two-thirds of cases in
this age group [38], which makes adult MB patients a
particularly attractive cohort for molecular-targeted thera-
pies. However, the exact proportions of subgroups and
genetic as well as transcriptomic differences between adult
and pediatric patients attributed to the same subgroups
have yet to be studied in more detail in larger cohorts.
Conclusions
While histology and the WHO classiﬁcation have not been
supplanted, it has become clear that histology alone is
inadequate for the diagnosis and classiﬁcation of ‘medullo-
blastoma’.Thecurrentgenerationofstudiessupportsamodel
in which transcriptionally similar tumors share clinical and
molecular features that will be useful in the clinic. The iden-
tiﬁcation of molecular subgroup will likely assume great
importance in the design and implementation of targeted
therapies. While transcriptionally driven classiﬁcations of
medulloblastoma will increase in importance over time, we
predict that classiﬁcation based on whole genome or exome
sequencing of tumor DNA will likely assume additional
importance as sequencing technologies become less expen-
sive, more widely available, and more reliable. While it is
clear that distinct molecular subgroups of medulloblastoma
exist and are clinically important, we should not lose sight of
the fact that there are also commonalities seen across the
subgroups, such as mutations in TP53 and MLL2 which are
seen in several subgroups [32, 34]. The challenges facing the
medulloblastoma community in moving forward are (1) to
achieve sufﬁcient inter-center co-operation to assemble large
cohorts of tumors for both discovery and validation, (2)
determine the true extent and nature of inter-tumoral hetero-
geneity as deﬁned by transcriptional proﬁling, and (3)
development ofclinically practical tests for medulloblastoma
subgroup assignment that will be feasible for both clinical
trials, and inclusion in the day to day clinical care of medul-
loblastoma patients across the globe.
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